Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 5
How BTK Inhibitors Differ From Current CSU Treatment Approaches
Published on:
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors offer a novel upstream approach, in contrast to current treatments that work downstream by either blocking released mediators (antihistamines), neutralizing circulating IgE (omalizumab), or broadly suppressing immune responses (immunosuppressants).
Video content above is prompted by the following:
- How do BTK inhibitors differ from the current treatment approach for chronic spontaneous urticaria (CSU) (antihistamines, omalizumab, immunosuppressants)?
